Skip to main content
Advertisement
Advertisement
USNA
USNA logo
USANA Health Sciences Inc
12.94
USD
Sponsored
-0.22
-1.67%
Nov 20, 15:59 UTC -5
Closed
exchange

After-Market

13.25

+0.31
+2.40%

USANA Health Sciences Inc (USNA) Earnings

USNA Earnings Reports

Positive Surprise Ratio

USNA beat 25 of 43 last estimates.

58%

Next Report

Date of Next Report
Feb 10, 2027
Estimate for Q4 26 (Revenue/ EPS)
$224.10M
/
$0.12
Implied change from Q3 26 (Revenue/ EPS)
+8.85%
/
-209.09%
Implied change from Q4 25 (Revenue/ EPS)
-0.93%
/
-80.00%

USANA Health Sciences Inc earnings per share and revenue

On Nov 03, 2026, USNA reported earnings of -0.11 USD per share (EPS) for Q3 26, missing the estimate of 0.11 USD, resulting in a -198.04% surprise. Revenue reached 205.88 million, compared to an expected 222.45 million, with a -7.45% difference. The market reacted with a -3.63% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 0.12 USD, with revenue projected to reach 224.10 million USD, implying an decrease of -209.09% EPS, and increase of 8.85% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Apnimed, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.62
Actual
-$0.99
Surprise
-59.11%
logo
Larimar Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.35
Actual
-$0.28
Surprise
+17.38%
logo
Lexeo Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.33
Actual
-$0.43
Surprise
-28.17%
logo
Galectin Therapeutics Inc.
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.05
Actual
-$0.04
Surprise
+21.57%
logo
NRX Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.21
Actual
-$0.05
Surprise
+76.94%
logo
Unicycive Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.32
Actual
-$0.25
Surprise
+21.88%
logo
Actinium Pharmaceuticals, Inc
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.19
Surprise
+23.45%
logo
Marker Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.11
Actual
-$0.10
Surprise
+15.97%
logo
Scienture Holdings, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$1.60
Actual
-$3.76
Surprise
-134.79%
logo
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.74
Actual
-$0.75
Surprise
-0.73%
FAQ
For Q3 2026, USANA Health Sciences Inc reported EPS of -$0.11, missing estimates by -198.04%, and revenue of $205.88M, -7.45% below expectations.
The stock price moved down -3.63%, changed from $14.87 before the earnings release to $14.33 the day after.
The next earning report is scheduled for Feb 10, 2027.
Based on -- analysts, USANA Health Sciences Inc is expected to report EPS of $0.12 and revenue of $224.10M for Q4 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement